Recent News

• 05.19.2025 - Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia
• 05.14.2025 - Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update
• 05.01.2025 - Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02
• 03.20.2025 - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update

Recent Filings

• 05.19.2025 - 8-K Current report
• 05.19.2025 - EX-99.1 EX-99.1
• 05.14.2025 - 8-K Current report
• 05.14.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.14.2025 - EX-99.1 EX-99.1
• 05.01.2025 - EX-99.1 EX-99.1
• 05.01.2025 - 8-K Current report
• 04.28.2025 - ARS Annual Report to Security Holders
• 04.28.2025 - DEF 14A Other definitive proxy statements
• 04.25.2025 - 4 Statement of changes in beneficial ownership of securities